Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and baseline characteristics of pooled treatment groups (total study population - safety population)a

From: Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia

  Ferumoxytol Treatment Group (n = 486) Iron Sucrose Treatment Group (n = 281) Total (N = 767)
Mean age, years (SD) 50.1 (15.75) 52.8 (16.06) 51.1 (15.90)
Mean weight, kg (SD) 70.9 (16.07) 76.0 (20.29) 72.8 (17.89)
Mean height, cm (SD) 165.8 (8.17) 166.5 (8.18) 166.0 (8.18)
Sex, n (%)
 Female 383 (78.8) 199 (70.8) 582 (75.9)
 Male 103 (21.2) 82 (29.2) 185 (24.1)
Race, n (%)
 American Indian/Alaskan Native 0 (0.0) 1 (0.4) 1 (0.1)
 Asian 51 (10.5) 18 (6.4) 69 (9.0)
 Black/African American 27 (5.6) 16 (5.7) 43 (5.6)
 Native Hawaiian/other Pacific Islander 2 (0.4) 1 (0.4) 3 (0.4)
 White 390 (80.2) 234 (83.3) 624 (81.4)
 Other/multiracial 16 (3.3) 11 (3.9) 27 (3.5)
Ethnicity, n (%)
 Hispanic/Latino 12 (2.5) 13 (4.6) 25 (3.3)
 Not Hispanic/Latino 474 (97.5) 268 (95.4) 742 (96.7)
CKD stage, n (%)    
 Stage 1 (eGFR ≥90 mL/min) 280 (57.6) 126 (44.8) 406 (52.9)
 Stage 2 (eGFR 60 to <90 mL/min) 104 (21.4) 59 (21.0) 163 (21.3)
 Stage 3 (eGFR 30 to <60 mL/min) 41 (8.4) 33 (11.7) 74 (9.6)
 Stage 4 (eGFR 15 to <30 mL/min) 23 (4.7) 20 (7.1) 43 (5.6)
 Stage 5 (eGFR <15 mL/min) 38 (7.8) 42 (14.9) 80 (10.4)
 Unknown 0 (0.0) 1 (0.4) 1 (0.1)
Dialysis status, n    
 Hemodialysis 34 36 70
ESA use, n (%) 45 (9.3) 40 (14.2) 85 (11.1)
  1. ESA erythropoiesis-stimulating agent, eGFR estimated glomerular filtration rate, Hgb hemoglobin, SD standard deviation
  2. aBaseline values obtained Day 1 prior to injection of study drug